| 2020-12 | Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy | 김광명; 윤홍열; 심만규; 양수아; 김진성; 문유정; 임승호; 조한희; 성준경 |
| 2021-02 | Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance | 김광명; 심만규; 최지웅; 양수아; 김정래; 김진성; 문유정; 송수경 |
| 2020-11 | Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death | 권익찬; 김광명; 윤홍열; 심만규; 최용환; 최지웅; 양수아; 김정래; 김진성; 문유정; 이재완; 전상민; 임승호 |
| 2020-12 | Epidermal growth factor (EGF)-based activatable probe for predicting therapeutic outcome of an EGF-based doxorubicin prodrug | 권익찬; 김광명; 류주희; 심만규; 김한영; 엄상훈; 양수아; 박주호; 성예진; 김은선 |
| 2020-05 | In Situ One-Step Fluorescence Labeling Strategy of Exosomes via Bioorthogonal Click Chemistry for Real-Time Exosome Tracking In Vitro and In Vivo | 김광명; 김인산; 윤홍열; 심만규; 양수아; 김진성; 문유정; 임승호; 송수경; 홍연선; 황광연 |
| 2020-04 | Necroptosis-Inducible Polymeric Nanobubbles for Enhanced Cancer Sonoimmunotherapy | 김광명; 심만규; 곽기정; 양수아; 임승호; 엄우람; 고혜원; 유동길; 이정진; 송애리; 박재형 |
| 2021-01 | Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography | 김광명; 윤홍열; 심만규; 양수아; 임승호; 송수경; 박순정; 강선웅; 임동권; 김병수; 문성환 |
| 2021-04 | Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy | 김광명; 선인철; 윤홍열; 양수아; 심만규; 황희숙 |
| 2021-07 | Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy | 김광명; 윤홍열; 조한희; 최지웅; 양수아; 김정래; 김진성; 문유정; 윤완수; 심만규; 황희숙 |
